Mohammad Taghi Bahreyni Toossi1, Mahdi Ghorbani2, Yasha Makhdoumi3, Mojtaba Taheri4, Fatemeh Homaee Shandiz3, Siavash Zahed Anaraki3, Ali Soleimani Meigooni5. 1. Medical Physics Research Center, Faculty of Medicine, Pardise Daneshgah, Mashhad University of Medical Sciences, Azadi Square, Mashhad, Iran. 2. North Khorasan University of Medical Sciences, Bojnurd, Iran. 3. Cancer Research Center, Radiation Oncology Department, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Reza Radiotherapy and Oncology Center, Fallahi No. 2, Mashhad, Iran. 5. Comprehensive Cancer Center of Nevada, Las Vegas, NV, USA.
Abstract
AIM: The aim of this work is to evaluate rectal and bladder dose for the patients treated for gynecological cancers. BACKGROUND: The GZP6 high dose rate brachytherapy system has been recently introduced to a number of radiation therapy departments in Iran, for treatment of various tumor sites such as cervix and vagina. MATERIALS AND METHODS: Our analysis was based on dose measurements for 40 insertions in 28 patients, treated by a GZP6 unit between June 2009 and November 2010. Treatments consisted of combined teletherapy and intracavitary brachytherapy. In vivo dosimetry was performed with TLD-400 chips and TLD-100 microcubes in the rectum and bladder. RESULTS: The average of maximum rectal and bladder dose values were found to be 7.62 Gy (range 1.72-18.55 Gy) and 5.17 Gy (range 0.72-15.85 Gy), respectively. It has been recommended by the ICRU that the maximum dose to the rectum and bladder in intracavitary treatment of vaginal or cervical cancer should be lower than 80% of the prescribed dose to point A in the Manchester system. In this study, of the total number of 40 insertions, maximum rectal dose in 29 insertions (72.5% of treatment sessions) and maximum bladder dose in 18 insertions (45% of treatments sessions) were higher than 80% of the prescribed dose to the point of dose prescription. CONCLUSION: In vivo dosimetry for patients undergoing treatment by GZP6 brachytherapy system can be used for evaluation of the quality of brachytherapy treatments by this system. This information could be used as a base for developing the strategy for treatment of patients treated with GZP6 system.
AIM: The aim of this work is to evaluate rectal and bladder dose for the patients treated for gynecological cancers. BACKGROUND: The GZP6 high dose rate brachytherapy system has been recently introduced to a number of radiation therapy departments in Iran, for treatment of various tumor sites such as cervix and vagina. MATERIALS AND METHODS: Our analysis was based on dose measurements for 40 insertions in 28 patients, treated by a GZP6 unit between June 2009 and November 2010. Treatments consisted of combined teletherapy and intracavitary brachytherapy. In vivo dosimetry was performed with TLD-400 chips and TLD-100 microcubes in the rectum and bladder. RESULTS: The average of maximum rectal and bladder dose values were found to be 7.62 Gy (range 1.72-18.55 Gy) and 5.17 Gy (range 0.72-15.85 Gy), respectively. It has been recommended by the ICRU that the maximum dose to the rectum and bladder in intracavitary treatment of vaginal or cervical cancer should be lower than 80% of the prescribed dose to point A in the Manchester system. In this study, of the total number of 40 insertions, maximum rectal dose in 29 insertions (72.5% of treatment sessions) and maximum bladder dose in 18 insertions (45% of treatments sessions) were higher than 80% of the prescribed dose to the point of dose prescription. CONCLUSION: In vivo dosimetry for patients undergoing treatment by GZP6 brachytherapy system can be used for evaluation of the quality of brachytherapy treatments by this system. This information could be used as a base for developing the strategy for treatment of patients treated with GZP6 system.
Authors: Mark J Rivard; Bert M Coursey; Larry A DeWerd; William F Hanson; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Jeffrey F Williamson Journal: Med Phys Date: 2004-03 Impact factor: 4.071
Authors: Bretislav Otahal; Martin Dolezel; Jakub Cvek; Ondrej Simetka; Jaroslav Klat; Lukas Knybel; Lukas Molenda; Eva Skacelikova; Ales Hlavka; David Feltl Journal: Rep Pract Oncol Radiother Date: 2014-05-01